A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Capivasertib (Primary) ; Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms RE-AKT
- 05 Aug 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 07 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Mar 2020.